Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Skyrizi (risankizumab) and Dupixent (dupilumab) are both biologic medications used to treat inflammatory conditions, but they belong to different medication classes and have distinct uses. Skyrizi is an interleukin antagonist used for plaque psoriasis, psoriatic arthritis, and Crohn's disease, while Dupixent is a monoclonal antibody used for eczema, asthma, and sinus congestion with nasal polyps, among other conditions. Skyrizi is typically administered as an injection every 2 to 3 months, whereas Dupixent is injected every other week or monthly, depending on the condition. Skyrizi is available in prefilled syringes, pens, and On-Body Injectors, while Dupixent comes in prefilled pens and syringes. Skyrizi's common side effects include injection site reactions, joint pain, and infections, while Dupixent may cause injection site reactions and eye inflammation. Both medications can interact with live vaccines, so it's important to discuss vaccine plans in advance with your prescriber. Skyrizi is not approved for use in children, whereas Dupixent can be used in children as young as 6 months for eczema.
Dupixent (dupilumab) is an injection that helps treat certain inflammatory conditions. This includes eczema, asthma, and chronic obstructive pulmonary disease (COPD), among others. It's a biologic medication known as an interleukin antagonist that lowers inflammation. Dupixent (dupilumab) comes as prefilled pens and prefilled syringes. It's injected under the skin of the belly or thighs (or in the back of the upper arm with someone's help). The dosing schedule depends on the condition you have, your age, and your weight. It's injected either every week, every 2 weeks, or every 4 weeks. Side effects include injection site reactions and eye problems.